Plain-English translation of NCT06664411 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination treatment called Pola-ZR2P for people who have just been diagnosed with diffuse large B-cell lymphoma (an aggressive type of blood cancer) and have never received chemotherapy before. The combination includes five different medications that work together to fight the cancer. Researchers want to see how well this medication works and how safe it is.
Diffuse large B-cell lymphoma is a serious cancer that needs strong treatment, and doctors are looking for more effective combinations that might help more patients go into remission. This study tests whether this new five-drug approach could be a better option than current standard treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the five-medication combination as your main cancer treatment. The study will track how well the treatment works, how your body responds, and what side effects you experience through regular visits and tests. Researchers will measure your response to the treatment and monitor your health over time to see if this combination is safe and effective.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Navy General Hospital, Beijing
Enrollment target
~80 participants
Started
September 2024
Primary completion
December 2029
Age range
14 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liren Qian, PhD
Navy General Hospital, Beijing
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.